scholarly journals Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

Oncotarget ◽  
2016 ◽  
Vol 7 (44) ◽  
pp. 71285-71297 ◽  
Author(s):  
Marc A. Schneider ◽  
Thomas Muley ◽  
Nicolas C. Kahn ◽  
Arne Warth ◽  
Michael Thomas ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up

Lung Cancer ◽  
2014 ◽  
Vol 83 (1) ◽  
pp. 78-82 ◽  
Author(s):  
Emilio Minatel ◽  
Marco Trovo ◽  
Jerry Polesel ◽  
Tania Baresic ◽  
Alessandra Bearz ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Malignant Pleural Mesothelioma ◽  
High Dose ◽  
Pleural Mesothelioma ◽  
Long Term Follow Up

Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique

2016 ◽  
Vol 11 (6) ◽  
pp. 444-447
Author(s):  
Francesco Paolo Caronia ◽  
Alfonso Fioretti ◽  
Mario Santini ◽  
Ettore Arrigo
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Early Stage ◽  
Skin Incision ◽  
Intercostal Space ◽  
Resected Specimen ◽  
Invasive Technique ◽  
Extrapleural Pneumonectomy ◽  
Pleural Mesothelioma ◽  
Sixth Intercostal Space

We report a novel less-invasive extrapleural pneumonectomy for early-stage malignant pleural mesothelioma without rib spreading. Our approach is unique and differed from the previously reported cases, because we used one skin incision and two small intercostal incisions with videothoracoscopic viewing without rib spreading. The pleural dissection and approach to the hilum for pneumonectomy were performed through a 4- to 5-cm port incision in the sixth intercostal space. Another 4- to 5-cm port was made in the eight intercostal space through the same skin incision and was used for diaphragm resection and reconstruction. At the end of the surgery, the skin incision was enlarged to 8 cm; through which and the first port in the sixth intercostal space, the resected specimen was retrieved. Three cycles of adjuvant chemotherapy followed by radiation therapy were administered. Eleven-month follow-up showed no recurrence.

scholarly journals Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting

2021 ◽  
Author(s):  
David M Waterhouse ◽  
Esmond D Nwokeji ◽  
Marley Boyd ◽  
John R Penrod ◽  
Janet L Espirito ◽  
...  
Keyword(s):  
Overall Survival ◽  
Malignant Pleural Mesothelioma ◽  
Median Overall Survival ◽  
Treatment Patterns ◽  
Pleural Mesothelioma ◽  
Community Practice ◽  
Community Centers ◽  
First Line ◽  
Third Line

Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line systemic anticancer therapy (SACT) at community centers. Median follow-up from diagnosis was 11.6 months. Pemetrexed + platinum was the most common first-line SACT; similar proportions of patients received cisplatin or carboplatin with pemetrexed. Only a small proportion of patients received second- and third-line therapies. Median overall survival for first-line SACT was 12.0 months (95% CI: 10.7–14.2). Results were similar with pemetrexed + cisplatin and pemetrexed + carboplatin. Median overall survival with second-line SACT was 6.4 months (95% CI: 5.1–7.6). Conclusion: There is a need for more effective SACTs for advanced malignant pleural mesothelioma.

Role of CT and modified Response Evaluation Criteria in Solid Tumors (RECIST criteria) in response evaluation of malignant pleural mesothelioma

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ass Prof .Dr., Khalid Esmat Allam ◽  
Hend Galal Eldeen Mohamed Ali Hassan ◽  
Basma Abdelbaset Mohamed
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Clinical Evaluation ◽  
Evaluation Criteria ◽  
Response Assessment ◽  
P Value ◽  
Pleural Mesothelioma ◽  
Response Evaluation ◽  
Malignant Pleural Mesothelioma Patient ◽  
Modified Recist

Abstract Background Malignant pleural mesothelioma is a rare and aggressive tumor that the growth pattern of it poses unique difficulties in measurement and response assessment . however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. Objectives The aim of this study is to assess the value of CT and modified RECIST criteria in follow up patients of malignant pleural mesothelioma patient during treatment with chemotherapy . Patients and methods We evaluated 20 malignant pleural mesothelioma patients undergoing to chemotherapy . Tumor thickness is measures perpendicular to the chest wall or mediastinum in two positions at three separate levels on thoracic CT scans. The sum of the six measurements defined a pleural unidimensional measure. A reduction of at least 30% on two occasions 6 weeks apart defined a partial response; an increase of 20% over the nadir measurement known as progressive disease. Patients who fulfilled the criteria for neither PR nor PD called CD .The validity of the modified criteria was gauged by clinical evaluation . Results In our study, CT and modified RECIST criteria were used as the method of choice in response evaluation of malignant pleural mesothelioma .Our study showed as follow up results of each group and comparison between clinical evaluation and modified RECIST criteria show over all accuracy 73.3% with P value = 0.03 and this results confirm accuracy of CT with modified RECIST criteria as good predictor of disease outcome . Conclusion These Modified RECIST criteria for tumor response correlate with clinical evaluation and can be used to measure outcome in pleural mesothelioma.

scholarly journals P.2.12 Clustering of malignant pleural mesothelioma in asbestos factories in a 29-years follow-up study to identify high-risk industries in taiwan

2019 ◽  
Vol 76 (Suppl 1) ◽  
pp. A90.2-A90
Author(s):  
Lukas Lee ◽  
Cheng-Kuan Lin ◽  
Chih-Hong Pan ◽  
Yawen Cheng ◽  
Yu-Yin Chang ◽  
...  
Keyword(s):  
Thermal Insulation ◽  
Malignant Pleural Mesothelioma ◽  
Screening Program ◽  
Causal Link ◽  
Sensitivity Analyses ◽  
Pleural Mesothelioma ◽  
Shipbuilding Industry ◽  
Asbestos Cement ◽  
Rate Ratios

ObjectiveExposure to asbestos is the major cause for malignant pleural mesothelioma (MPM) but the causal link of individual cases is difficult to establish for lack of exposure information and long disease latency.MethodsWe established a retrospective cohort of workers employed in asbestos industries during the period of 1950–1989 and the occurrence of MPM during the period of 1980–2009 was examined with the Taiwan Cancer Registry. Estimated rate ratios (eRR) were computed for each factory where any case of MPM was diagnosed by assuming Poisson distribution with a minimal latency of 20 years.ResultsA total of 18 MPM (17 males, 1 female) in 8 factories were found. The incidence rate of MPM for the 8 factories was 18.0 per million, ranging from 6.2 per million (military factory) to 268.2 per million (asbestos cement). We observed significantly increased risks for MPM in asbestos cement, thermal insulation and shipbuilding industries, with eRR (genders combined) of 113.6, 87.5, and 15.8 respectively. The sensitivity analyses considering latency showed similar findings in latency ≥30 years, and the shipbuilding industry presented a significant eRR given a latency ≥40 years. The gender-specific eRR showed similar results in men, but high eRR of 729.6 was observed in an asbestos cement factory where a female MPM was diagnosed.ConclusionsThis nationwide study in Taiwan comprehensively showed different asbestos manufacturing processes, including asbestos cement, thermal insulation, and shipbuilding industries, at significantly increased risks for MPM. We recommend to establish a medical screening program for workers previously exposed to asbestos to identify MPM and other asbestos-related diseases at an earlier stage.

Sign in / Sign up

Export Citation Format

Share Document